ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Exploring the mechanism of anti-chronic heart failure effect of qiweiqiangxin CYRILLIC CAPITAL LETTER BYELORUSSIAN-UKRAINIAN I granules based on metabolomics

Zhong, Wanru; Li, Yihua; Zhong, Haixiang; Cheng, Yuanyuan; Chen, Qi; Zhao, Xinjun; Liu, Zhongqiu*; Li, Rong*; Zhang, Rong*广州中医药大学; 1
Frontiers in Pharmacology2023-2-13DOI: 10.3389/fphar.2023.1111007
12阅读
引用收藏
分享

摘要

Background: Qiweiqiangxin CYRILLIC CAPITAL LETTER BYELORUSSIAN-UKRAINIAN I granules (QWQX CYRILLIC CAPITAL LETTER BYELORUSSIAN-UKRAINIAN I) is a traditional Chinese medicine preparation based on the basic theory of traditional Chinese medicine, which produces a good curative effect in treating chronic heart failure (CHF). However, its pharmacological effect and potential mechanism for CHF remain unknown.Aim of the study: The purpose of this study is to clarify the efficacy of QWQX CYRILLIC CAPITAL LETTER BYELORUSSIAN-UKRAINIAN I and its possible mechanisms.Materials and methods: A total of 66 patients with CHF were recruited and randomly assigned to the control or QWQX CYRILLIC CAPITAL LETTER BYELORUSSIAN-UKRAINIAN I groups. The primary endpoint was the effect of left ventricular ejection fraction (LVEF) after 4 weeks of treatment. The LAD artery of rats was occluded to establish the model of CHF. Echocardiography, HE and Masson staining were performed to evaluate the pharmacological effect of QWQX CYRILLIC CAPITAL LETTER BYELORUSSIAN-UKRAINIAN I against CHF. Ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS) untargeted metabolomics was to screen endogenous metabolites in rat plasma and heart and elucidate the mechanism of QWQX CYRILLIC CAPITAL LETTER BYELORUSSIAN-UKRAINIAN I against CHF. Results: In the clinical study, a total of 63 heart failure patients completed the 4-week follow-up, including 32 in the control group and 31 in QWQX CYRILLIC CAPITAL LETTER BYELORUSSIAN-UKRAINIAN I group. After 4 weeks of treatment, LVEF was significantly improved in QWQX CYRILLIC CAPITAL LETTER BYELORUSSIAN-UKRAINIAN I group compared with the control group. In addition, the patients in QWQX CYRILLIC CAPITAL LETTER BYELORUSSIAN-UKRAINIAN I group had better quality of life than the control group. In animal studies, QWQX CYRILLIC CAPITAL LETTER BYELORUSSIAN-UKRAINIAN I significantly improved cardiac function, decreased B-type natriuretic peptide (BNP) levels, reduced inflammatory cell infiltration, and inhibited collagen fibril rate. Untargeted metabolomic analysis revealed that 23 and 34 differential metabolites were screened in the plasma and heart of chronic heart failure rats, respectively. 17 and 32 differential metabolites appeared in plasma and heart tissue after QWQX CYRILLIC CAPITAL LETTER BYELORUSSIAN-UKRAINIAN I treatment, which were enriched to taurine and hypotaurine metabolism, glycerophospholipid metabolism and linolenic acid metabolism by KEGG analysis. LysoPC (16:1 (9Z)) is a common differential metabolite in plasma and heart, which is produced by lipoprotein-associated phospholipase A2 (Lp-PLA2), hydrolyzes oxidized linoleic acid to produce pro-inflammatory substances. QWQX CYRILLIC CAPITAL LETTER BYELORUSSIAN-UKRAINIAN I regulates the level of LysoPC (16:1 (9Z)) and Lp-PLA2 to normal.Conclusion: QWQX CYRILLIC CAPITAL LETTER BYELORUSSIAN-UKRAINIAN I combined with western medicine can improve the cardiac function of patients with CHF. QWQX CYRILLIC CAPITAL LETTER BYELORUSSIAN-UKRAINIAN I can effectively improve the cardiac function of LAD-induced CHF rats through regulating glycerophospholipid metabolism and linolenic acid metabolism-mediated inflammatory response. Thus, QWQX I might provide a potential strategy for CHF therapy.

学科与关键词

关键词
chronic heart failurerandomized controlled clinical trialspharmacodynamicsmetabolomicspathway analysisefficacy
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2023-02-13
卷期
第 14 卷
页码
1111007
DOI
10.3389/fphar.2023.1111007
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81930114]; Key-Area Research and Development Program of Guangdong Province Special Project for Research and Development in Key areas of Guangdong Province [2020B1111100004]; Science and Technology Program of Guangzhou [202102021262, 202201020356]; High-level University Discipline Collaborative Innovation Team of GZUCM [2021XK11, 2021XK52]; Natural Science Foundation of Guangdong Province [2021A1515220046]

作者

  • Z

    Zhong, Wanru (第一作者)

    guangzhou univ chinese med

  • L

    Li, Yihua

    1 · guangzhou univ chinese med

查看全部 9 位作者收起作者
  • Z

    Zhong, Haixiang

    guangzhou univ chinese med

  • C

    Cheng, Yuanyuan

    guangzhou univ chinese med

  • C

    Chen, Qi

    1 · guangzhou univ chinese med

  • Z

    Zhao, Xinjun

    1 · guangzhou univ chinese med

  • L

    Liu, Zhongqiu (通讯)

    guangzhou univ chinese med

  • L

    Li, Rong (通讯)

    1 · guangzhou univ chinese med

  • Z

    Zhang, Rong (通讯)

    guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417